Literature DB >> 7624839

Chloroquine inhibits stimulated platelets at the arachidonic acid pathway.

R Nosál1, V Jancinová, M Petríková.   

Abstract

Chloroquine inhibited arachidonic acid liberation from membrane phospholipids of thrombin- and A23187- stimulated platelets. In addition, it dose-dependently inhibited stimulated malondialdehyde formation and thromboxane B2 generation in the same platelets. The linear correlation between the inhibition of arachidonic acid liberation and malondialdehyde formation indicated that chloroquine inhibited activated phospholipase A2 in thrombin-stimulated platelets, similarly as it does in different cells and tissues. Yet, the nonlinear relationship between arachidonic acid liberation along with malondialdehyde formation and thromboxane generation as well as aggregation suggest that phospholipase A2 does not seem to be the only site of chloroquine action. Rather, it may affect platelets either at other levels of the arachidonic acid cascade too, or at some different stimulatory pathways, like intraplatelet calcium mobilisation, phosphoinositide cycle, calmodulin and protein kinase C activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624839     DOI: 10.1016/0049-3848(95)00028-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Effect of chloroquine on arachidonic acid pathway in isolated mast cells.

Authors:  K Drábiková; J Pecivová; R Nosál
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

2.  The H1-histamine antagonist Dithiaden inhibits human platelets in vitro.

Authors:  R Nosál; V Jancinová; E Danihelová
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

3.  Plasma metabolomics reveals membrane lipids, aspartate/asparagine and nucleotide metabolism pathway differences associated with chloroquine resistance in Plasmodium vivax malaria.

Authors:  Karan Uppal; Jorge L Salinas; Wuelton M Monteiro; Fernando Val; Regina J Cordy; Ken Liu; Gisely C Melo; Andre M Siqueira; Belisa Magalhaes; Mary R Galinski; Marcus V G Lacerda; Dean P Jones
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

Review 4.  COVID-19: Immunology and treatment options.

Authors:  Susanna Felsenstein; Jenny A Herbert; Paul S McNamara; Christian M Hedrich
Journal:  Clin Immunol       Date:  2020-04-27       Impact factor: 3.969

Review 5.  Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.

Authors:  Amit Pal; Anil Pawar; Kalyan Goswami; Praveen Sharma; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2020-06-10

Review 6.  Hydroxychloroquine: from malaria to autoimmunity.

Authors:  Ilan Ben-Zvi; Shaye Kivity; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

7.  Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?

Authors:  Christian A Devaux; Laurence Camoin-Jau; Jean-Louis Mege; Didier Raoult
Journal:  J Microbiol Immunol Infect       Date:  2021-01-05       Impact factor: 4.399

Review 8.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.